Seasonal Affective Disorder Market is expected to grow at a CAGR of 4.5%in the forecast period of 2017-2024

 Seasonal Affective Disorder Market

Seasonal affective disorder is a type of depression which occurs usually with the season change. It occurs mostly in women and in the age group of 15 to 55 years during winters due to reducing light exposure to sunlight or to the people who live far away from equator where daylight hours are very short. 

Access Full Report at https://www.databridgemarketresearch.com/reports/global-seasonal-affective-disorder-market

Some of the factors boosting the Seasonal Affective Disorder Market growth are:

  • Rise in geriatric population: One of the most important factors behind the growth of the seasonal affective disorder is the rise in the age of the people which catches many diseases in the body. Some of the major symptoms are hopelessness, increased appetite and weight gain which signifies the occurrence of disease. At the growing age, body is prone to diseases or the above factors affecting the health of the person
  • Growing market for generic drugs: Another factor that is inducing positive demand for seasonal affective disorder is the introduction of genetic drugs in the market. They help to protect the body by maintaining the body cells and tissues strong. With proper medication and use of genetic drugs, body does not get prone to diseases which will further help to uplift the market growth

Strategic launches of products and expansion of businesses undertaken by market players:

  • In March 2019, Johnson & Johnson Services, Inc approved their product spravato nasal spray from FDA. It helps to treat patients who suffered from seasonal affective disorder and depression problems. This drug is referred to those patients who are not recovered from 2-3 antidepressants prescribed by the physicians. This product will increase the market share of the company thereby improve the healthcare market trends.
  • In July 2017, Jubilant Life Sciences Limited received approval from the U.S. Health Regulator of their Buprapion Hydrochloride extended release tablet which is used to treat seasonal affective disorder. It is the advanced version of Wellbutrin Xl used to treat depressive disorders.

The market is segmented on the basis of type as fall and winter sad, spring and summer sad, others; diagnosis as physical exams, lab tests, psychological evaluation; treatment as phototherapy, medications, psychotherapy, counseling; end user as hospital, clinics, academic institutes, medical research centers.; distribution channel as hospital pharmacies, retail pharmacies and drug stores, online pharmacies.

“According to Data Bridge Market Research, Global Seasonal Affective Disorder Market is expected to growing with a steady CAGR of 4.5% during the forecast period of 2017 to 2024”

Some of the major players operating in market are Janssen Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc., Sanofi, Eli Lilly and Company, Biogen, Bristol-Myers Squibb Company, Baxter, Novartis AG, Shire, AstraZeneca, Beurer GmbH, Koninklijke Philips N.V., Lumie, Verilux, Inc., AbbVie Inc., ALLARGAN, F. Hoffmann-La Roche Ltd., Henry Schein, Inc. among others.

With the focus of authorities of different regions on promotion of genetic drugs that can be helpful for the patients suffering from seasonal affective disorder, manufacturers of different pharmaceutical domain are not just providing drugs, but going various innovations to improve the quality of the drug supplied to their customers. Physicians are doing certain experiments to cure the problem without getting prone to genetic drugs.

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/